Pipeline

Solid Tumor Program

TScan is developing multiplex TCR-T therapy to treat solid tumors. Our vision is to expand the ImmunoBank, a repository of TCRs across multiple targets and HLA types, to provide tailored therapies for patients with various types of solid tumors.
  • Our TCR-T therapies are designed to be administered as both a single product or in combination with each other as a multiplexed treatment to help reduce the risk of resistance driven by target loss or HLA loss of heterozygosity.
  • Targets are both shared among patients with the same cancer type but are also expressed across different solid tumor types, enabling clinical development in multiple indications.

TScan is building the ImmunoBank of TCRs to enable multiplex TCR-T cell therapy

  • Targets are frequently expressed in high incidence solid tumors that are heterogenous by nature, including NSCLC, sarcoma, head & neck, cervical, anal and genital cancer.
  • We plan to combine these product candidates together as a multiplex TCR-T therapy to overcome tumor heterogeneity and target and HLA loss.
  • We believe that by targeting more than one antigen expressed in a tumor, we are positioned to improve response rates as well as duration of response in these difficult-to-treat solid tumor indications.